Analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) in a research note issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
Brainstorm Cell Therapeutics Trading Up 6.3 %
BCLI stock opened at $2.72 on Tuesday. The firm has a 50 day moving average of $2.80 and a 200-day moving average of $3.03. The firm has a market capitalization of $99.24 million, a P/E ratio of -4.25 and a beta of 0.05. Brainstorm Cell Therapeutics has a 12 month low of $2.52 and a 12 month high of $4.46.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) last announced its quarterly earnings data on Monday, May 16th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). During the same quarter in the prior year, the firm earned ($0.19) earnings per share. Sell-side analysts predict that Brainstorm Cell Therapeutics will post -0.61 EPS for the current year.
Hedge Funds Weigh In On Brainstorm Cell Therapeutics
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
- Get a free copy of the StockNews.com research report on Brainstorm Cell Therapeutics (BCLI)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook Brightens
- Deep Value High Yield Newell Brands Is Ready To Bottom
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.